title: Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
abstract: Beta(2)-microglobulin (beta(2)m)-derived peptides are minor transplantation Ags in mice as beta(2)m-positive skin grafts (beta(2)m(+/+)) are rejected by genetically beta(2)m-deficient recipient mice (beta(2)m(-/-)). We studied the effector pathways responsible for the rejection induced by beta(2)-microglobulin-derived minor transplantation Ags. The rejection of beta(2)m(+/+) skin grafts by naive beta(2)m(-/-) mice was dependent on both CD4 and CD8 T cells as shown by administration of depleting mAbs. Experiments performed with beta(2)m(-/-)CD8(-/-) double knockout mice grafted with a beta(2)m(+/+) MHC class I-deficient skin showed that sensitized CD4 T cells directed at beta(2)m peptides-MHC class II complexes are sufficient to trigger rapid rejection. Rejection of beta(2)m(+/+) grafts was associated with the production of IL-5 in vitro, the expression of IL-4 and IL-5 mRNAs in the grafted tissue, and the presence within rejected grafts of a considerable eosinophil infiltrate. Blocking IL-4 and IL-5 in vivo and depleting eosinophils with an anti-CCR3 mAb prevented graft eosinophil infiltration and prolonged beta(2)m(+/+) skin graft survival. Lymphocytes from rejecting beta(2)m(-/-) mice also displayed an increased production of IFN-gamma after culture with beta(2)m(+/+) minor alloantigens. In vivo neutralization of IFN-gamma inhibited skin graft rejection. Finally, beta(2)m(+/+) skin grafts harvested from B6(lpr/lpr) donor mice, which lack a functional Fas molecule, survived longer than wild-type beta(2)m(+/+) skin grafts, showing that Fas-Fas ligand interactions are involved in the rejection process. We conclude that IL-4- and IL-5-dependent eosinophilic rejection, IFN-gamma-dependent mechanisms, and Fas-Fas ligand interactions are effector pathways in the acute rejection of minor transplantation Ags.
authors.affiliation: Laboratory of Experimental Immunology, Université Libre de Bruxelles, and Department of Nephrology, Hôpital Erasme, Brussels, Belgium. msurquin@ulb.ac.be
authors.forename: Murielle
authors.initials: M
authors.lastname: Surquin
authors.forename: Alain
authors.initials: A
authors.lastname: Le Moine
authors.forename: Véronique
authors.initials: V
authors.lastname: Flamand
authors.forename: Nathalie
authors.initials: N
authors.lastname: Nagy
authors.forename: Katia
authors.initials: K
authors.lastname: Rombaut
authors.forename: François-Xavier
authors.initials: FX
authors.lastname: Demoor
authors.forename: Patrick
authors.initials: P
authors.lastname: Stordeur
authors.forename: Isabelle
authors.initials: I
authors.lastname: Salmon
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Guéry
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
authors.forename: Daniel
authors.initials: D
authors.lastname: Abramowicz
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens / Q000096:biosynthesis / Q000235:genetics; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002465:Cell Movement / Q000235:genetics / Q000276:immunology*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D004804:Eosinophils / Q000276:immunology / Q000473:pathology*; D053222:Fas Ligand Protein; D005260:Female; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D007274:Injections, Intraperitoneal; D008024:Ligands; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015778:Minor Histocompatibility Antigens / Q000235:genetics / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D016038:Skin Transplantation / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000637:transplantation; D018418:Th2 Cells / Q000276:immunology*; D019172:Transplantation Conditioning / Q000379:methods; D001613:beta 2-Microglobulin / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D019014:fas Receptor / Q000378:metabolism / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D016827:CD8 Antigens; D016207:Cytokines; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008024:Ligands; D008562:Membrane Glycoproteins; D015778:Minor Histocompatibility Antigens; D012333:RNA, Messenger; D001613:beta 2-Microglobulin; D019014:fas Receptor